CNC · Centene Corporation · Stock research

Current Thesis

The post-print bid has kept extending. That clears both moving-average levels as they stood on 2026-08-04 — the 20-day at $65.16 and the 50-day at $63.85 — and puts the stock inside a 52-week range of $25.08–$69.36 at a $32.49B market cap. The two intervening sessions are not restated here. The only Centene release dated in that gap was a $350,000 flood-relief commitment from Superior HealthPlan and the Centene Foundation on 2026-08-05, so no company disclosure is attached to the 08-07 move.

The leg being underwritten is unchanged: a shrinking book converting a repaired underwriting margin into per-share value, with 2027 volume unresolved until December. Two dated events now sit inside four sessions. CMS requires every rate filing containing a qualified health plan to be finalized by 3:00 p.m. EDT on 2026-08-12 — but that deadline binds filings in states on the HealthCare.gov platform; state-based exchanges off that platform set their own date, no later than 2026-10-15 (CMS revised PY2027 QHP Data Submission and Certification Timeline Bulletin). Marketplace price for 2027 therefore locks in two stages, not one. Second, Centene delivered notice on 2026-07-29 to redeem $500,000,000 of its 4.25% notes due 2027-12-15 on 2026-08-13 at par plus accrued interest, leaving roughly $568,664,000 outstanding (Form 8-K, 2026-07-29).

Theme status: SATURATED. Dating it: eight sell-side target revisions since the 2026-07-28 print, all raises, no cuts — and the two most recent are the two lowest, JP Morgan $67 with a Neutral on 2026-08-04 and Baird $66 with a Neutral on 2026-07-29, both struck near where the stock already traded. Consensus across 21 analysts is $71.67, which stockanalysis.com scored as 8.97% upside on 2026-08-07; early-August consensus roundups put the panel at 8 Strong Buy, 12 Hold, 1 Strong Sell. Targets are following the tape.

Bullish and bearish views on Centene Corporation

The model's bull view on Centene Corporation (CNC), in brief: Q2 2026 (2026-07-28): adjusted EPS $2.51 versus $1.08 consensus; revenue $53.579B versus $47.617B; net income $1.09B against a $253M loss a year earlier. The bear view: Volume is guided down: on 2026-07-28 the CEO said year-end membership would be lower than the prior outlook. Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-28): adjusted EPS $2.51 versus $1.08 consensus; revenue $53.579B versus $47.617B; net income $1.09B against a $253M loss a year earlier.
• FY2026 adjusted EPS guidance raised to more than $4.80 from more than $3.40 (consensus $3.52); revenue $193.5–197.5B; full-year HBR 90.5%–91.3%; GAAP EPS more than $3.11.
• Every segment cost ratio improved in Q2: consolidated HBR 89.6% from 93.0%; Commercial/ACA 79.2% from 90.6%; Medicaid 93.9% from 94.9%; Medicare 89.5% from 90.9%. Adjusted SG&A ratio 6.9% versus 7.1%.
• On the 2026-07-28 call the FY2026 Medicaid composite rate forecast went to roughly 5% from roughly 4.5%; 2026 marketplace pretax margin guide 4.5%–5.0%, Medicare Part D pretax to more than 3% against an initial 2%.
• Deleveraging is being executed in cash: total debt $16,105M at 2026-06-30 versus $17,401M at 2025-12-31 (Q2 10-Q); $1,289M of senior notes repurchased in H1; and the 2026-08-13 redemption retires another $500M at par.
• Illinois re-procurement retained: subsidiary Meridian Health Plan of Illinois was awarded a HealthChoice Illinois contract announced 2026-07-09, four-year term from 2027-01-01 across all 102 counties, against a book of more than 596,000 current Medicaid enrollees.
• KFF's 2026-08-03 review of 276 insurers across all 50 states and DC puts the median proposed 2027 marketplace increase at about 15%, with 63% of filings between 10% and 25% — repricing is industry-wide.

Bear Case

• Volume is guided down: on 2026-07-28 the CEO said year-end membership would be lower than the prior outlook. Total at-risk membership was 25.9M at 2026-06-30 against 28.0M a year earlier.
• The group is marked on enrollment, not on EPS. MOH beat and fell 12% on 2026-07-23; ELV's 2026-07-15 guidance raise set off a sector selloff; CNC's own 131% EPS surprise produced a 5.1% decline on 2026-07-28.
• Q2 carried roughly $0.50 of prior-year settlement contribution (Q2 call, 2026-07-28), which does not repeat in Q3.
• The enhanced premium tax credits expired 2025-12-31. Senate votes on competing extensions in December 2025 advanced nothing; the House passed HR 1834 230-196 on 2026-01-08; ASTHO's 2026-01-20 update described the Senate path as unclear, with a bipartisan CARE Act draft proposing a two-year extension plus minimum premium payments and income caps. No Senate passage has been reported since.
• CMS projects its 2027 payment-parameters rule alone cuts marketplace enrollment by 1.2–2M, before pricing effects.
• Twice-a-year Medicaid eligibility redeterminations begin in December 2026; the Urban Institute estimated on 2026-07-16 that 2–3.1M people could lose coverage. Centene carried 12.1M Medicaid members at quarter-end.
• Part D premium stabilization was not renewed for 2027 (WSJ, 2026-07-28), under a book whose 2026 margin guide was just raised.
• The only open-market insider transaction reported in 2026 is a sale: Director Kenneth A. Burdick, 80,000 shares at $64.55 ($5.164M), cutting his holding 22% to 283,580 shares (Form 4, 2026-06-11). Every other 2026 Form 4 is a zero-consideration award.

Setup & Price Structure

• Sequence: $64.07 close on 2026-08-04, $65.77 close on 2026-08-07 (+2.45%). The 2026-08-04 session low of $63.48 was the fifth consecutive higher low since the print; RSI(14) read 49.97 that day (Barchart).

• Overhead reference is the 52-week high of $69.36; the 52-week low is $25.08 (stockanalysis.com, 2026-08-07).
• Positioning observables: eight target raises and zero cuts between 2026-07-28 and 2026-08-04; the high marks (Barclays $80 and Truist $80 on 2026-07-29, Bernstein $79 on 2026-08-03) sit above the $71.67 consensus while the newest sit within a few dollars of spot. Twelve of 21 ratings are Hold. Insider flow in 2026 is one sale and no purchases.
• Capital return skews to bondholders: $33M of common stock repurchased in H1 against $1,289M of senior notes, plus the $500M par redemption dated 2026-08-13. No equity issuance into the rally is disclosed in the Q2 10-Q; 493,995 thousand shares were outstanding as of 2026-07-24.

Catalyst Calendar (next 30 days)

• 2026-08-12 — CMS deadline, 3:00 p.m. EDT, for finalizing PY2027 rate filings containing a qualified health plan in HealthCare.gov-platform states.
• 2026-08-13 — $500M partial redemption of the 4.25% notes due 2027-12-15, at 100% plus accrued; roughly $568,664,000 remains outstanding.
• 2026-08-14 — Q2 2026 13F filing deadline.
• 2026-09-08 — CMS review window for PY2027 QHP applications closes; certification agreements sent to issuers.

What Would Change Our Mind

The structure that has carried this since 2026-07-28 is the run of higher lows and the 50-day zone reclaimed on 2026-08-03. Losing that is the break: a weekly close below $63 undoes the reclaim measured at $63.85 on 2026-08-04 and ends the higher-low sequence; a weekly close below $56 additionally cuts under the July consolidation shelf and the post-print low. On the fundamental side, three observables would flip the read: 2026-08-12 passing with the 2027 rate position unchanged and no re-rating in the days after; a Q3 print (~2026-10-27, est.) that trims the more-than-$4.80 FY guide or leaves Medicaid HBR above the roughly 93.5% target it printed 93.9% against; or year-end membership landing materially below the Q2 marks of about 3.5M marketplace and 12.1M Medicaid.

The reverse case has an observable too. A Senate floor vote passing an enhanced-premium-tax-credit extension ahead of the November open-enrollment start would reset the 2027 volume assumption that the SATURATED label rests on, and would do it before any company disclosure.

Correlation Notes

• CNC trades with the managed-care complex on policy headlines rather than on its own execution: ELV's 2026-07-15 raise moved the whole group lower, MOH fell 12% on 2026-07-23, and CNC fell 5.1% on its own beat on 2026-07-28.
• Revenue is set by state Medicaid rate cycles and CMS rulemaking, so the regulatory calendar — 2026-08-12, 2026-09-08, the December redetermination start — carries more of the variance than quarterly execution.
• With about 3.5M marketplace members at 2026-06-30, subsidy-legislation headlines hit CNC differently from Medicaid-weighted peers; conversely, the 12.1M Medicaid book ties it to the same December 2026 redetermination shock those peers face.
• Premium and service revenue ran $44.4B in Q2 on a thin underwriting spread, so a percentage-point move in HBR swings EPS more than any single membership headline.